Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.

PURPOSE We sought to elucidate long-term changes in health-related quality-of-life (HRQOL) outcomes by prospectively re-evaluating a well-characterized cohort of prostate cancer (PC) survivors 4 to 8 years after primary treatment. PATIENTS AND METHODS Patients who had been evaluated previously at a median of 2.6 years after radical prostatectomy (RP), external radiation (three-dimensional conformal radiation therapy [3-D CRT]), or brachytherapy (BT) were recontacted at a median of 6.2 years after treatment. The clinical relevance of long-term HRQOL impairment among survivors was established by comparison with controls of similar age. Factors associated with HRQOL changes during this interval were evaluated. RESULTS Of the 964 eligible men, 709 (73.5%) completed measurable questionnaires. In four domains (urinary irritative-obstructive, urinary incontinence, bowel, and sexual), significant HRQOL differences were detected for at least one of the therapy groups, compared with controls (all P < .05). During the 4-year interval, significant improvement was observed for the urinary irritative-obstructive (P < .0001) and bowel (P < .0001) domains among BT patients, whereas urinary incontinence HRQOL worsened for both the BT (P = .0017) and 3-D CRT (P = .0008) treatment groups. Overall sexual HRQOL deteriorated for the 3-D CRT cohort (P = .0017), as well as for controls (P = .0136). Among RP patients, significant HRQOL changes were not observed. CONCLUSION During a 4-year interval from earlier to longer-term phases of PC treatment survivorship, sexual, urinary, and bowel dysfunction remain significant concerns among early-stage PC treatment survivors, compared with control men. Although postprostatectomy HRQOL remains relatively stable during this interval, disease-specific HRQOL continues to evolve among men treated with BT and 3-D CRT.

[1]  W. Catalona,et al.  Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. , 1990, The Journal of urology.

[2]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[3]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[4]  P. Schellhammer,et al.  Results of radical prostatectomy in men with clinically localized prostate cancer. , 1996, JAMA.

[5]  W Cavanagh,et al.  Should brachytherapy be considered a therapeutic option in localized prostate cancer? , 1996, The Urologic clinics of North America.

[6]  J A Smith,et al.  Results of radical prostatectomy in men with clinically localized prostate cancer. , 1996, JAMA.

[7]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[8]  J. Richie,et al.  Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. , 1997, Journal of the National Cancer Institute.

[9]  P. Kantoff,et al.  Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Richie,et al.  Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Lubeck,et al.  Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. , 1998, The Journal of urology.

[12]  N. Aaronson,et al.  Health related quality of life in men with prostate cancer. , 2003, The Journal of urology.

[13]  R H Brook,et al.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. , 1998, Medical care.

[14]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[15]  M. Litwin,et al.  Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. , 1999, Journal of Clinical Oncology.

[16]  M. Litwin Examining health-related quality of life in men treated for prostate cancer , 1999, World Journal of Urology.

[17]  P. Fransson,et al.  Late side effects unchanged 4–8 years after radiotherapy for prostate carcinoma , 1999, Cancer.

[18]  D. Ash,et al.  Short‐term morbidity and acceptability of 125iodine implantation for localized carcinoma of the prostate , 1999, BJU international.

[19]  J. Stanford,et al.  Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. , 1999, Journal of the National Cancer Institute.

[20]  R A Stephenson,et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. , 2000, Journal of the National Cancer Institute.

[21]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[22]  M. Litwin,et al.  Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. , 2000, The Journal of urology.

[23]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[24]  W. Lee,et al.  A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[25]  H. D. de Koning,et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. P. Mitchell,et al.  Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. , 2001, The Journal of urology.

[27]  D. Katz,et al.  Effect of Treatment on Quality of Life Among Men With Clinically Localized Prostate Cancer , 2001, Medical care.

[28]  M. Litwin,et al.  Life after radical prostatectomy: a longitudinal study. , 2001, The Journal of urology.

[29]  John T. Wei,et al.  Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Klein,et al.  The use of treatments for erectile dysfunction among survivors of prostate carcinoma , 2002, Cancer.

[31]  John T. Wei,et al.  Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. , 2002, Urology.

[32]  Colin B Begg,et al.  Variations in morbidity after radical prostatectomy. , 2002, The New England journal of medicine.

[33]  J. Blasko,et al.  Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. , 2002, Seminars in radiation oncology.

[34]  A. Henderson,et al.  125Iodine prostate brachytherapy: outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics , 2002, BJU international.

[35]  R. Stock,et al.  Complications following permanent prostate brachytherapy. , 2002, European urology.

[36]  Ronald C. Chen,et al.  Time course and predictors of symptoms after primary prostate cancer therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Penson,et al.  Quality of life after treatment for prostate cancer , 2003 .

[38]  D. Lubeck,et al.  Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE. , 2003, The Journal of urology.

[39]  K. Wallner,et al.  Minimizing prostate brachytherapy-related morbidity. , 2003, Urology.

[40]  S. Mehta,et al.  Role of surgeon volume in radical prostatectomy outcomes. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Stanford,et al.  General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Stanford,et al.  Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. , 2004, Journal of the National Cancer Institute.

[43]  Butler Wm,et al.  Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905. , 2006 .